Sugi Predict

Sugi Predict / Compounds / SCHEMBL2827976

SCHEMBL2827976

SCHEMBL2827976

Cc1cc(CC(=O)O)n(C)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.46
▸ KDM4E B2RXH2 2/20 0.45
▸ FFAR1 O14842 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ DAO P14920 1/20 0.40
▸ P2RX7 Q99572 1/20 0.39
▸ PTGS2 P35354 2/20 0.38
▸ CXCL8 P10145 1/20 0.38
▸ AKR1B1 P15121 1/20 0.38
▸ PTGS1 P23219 1/20 0.38
▸ GLO1 Q04760 1/20 0.38
▸ ABCB11 O95342 1/20 0.38
▸ APAF1 O14727 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ KCNH2 Q12809 2/20 0.37
▸ TSHR P16473 1/20 0.37
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ PTGDR2 Q9Y5Y4 1/20 0.36
▸ GRIN2B Q13224 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20353295 0.85 SMN1; SMN2 (0.43) LMNAKDM4EFFAR1SMN1; SMN2DAO
SCHEMBL4085587 0.83 HTT (0.47) LMNAKDM4EFFAR1SMN1; SMN2DAO
SCHEMBL12492462 0.83 SMN1; SMN2 (0.42) LMNAKDM4EFFAR1SMN1; SMN2DAO
SCHEMBL3930006 0.81 KDM4E (0.50) LMNAKDM4EFFAR1SMN1; SMN2DAO
SCHEMBL6035580 0.81 KDM4E (0.36) LMNAKDM4EPTGS2CXCL8AKR1B1
SCHEMBL24589257 0.80 SMN1; SMN2 (0.51) LMNAKDM4EFFAR1SMN1; SMN2DAO
Hydrochloric Acid SCHEMBL27848637 0.79 GABRA5 (0.40) LMNAKDM4EPTGS2CXCL8AKR1B1
SCHEMBL17473347 0.79 KDM4E (0.35) LMNAKDM4EPTGS2CXCL8AKR1B1
SCHEMBL2827324 0.79 KDM4E (0.51) LMNAKDM4EFFAR1SMN1; SMN2DAO
SCHEMBL2824324 0.79 KDM4E (0.48) LMNAKDM4EFFAR1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026103730-A1 DIAZAHETEROCYCLIC DERIVATIVE OF PYRIDOARYL GROUP HAVING KAPPA RECEPTOR ANTAGONISTIC ACTIVITY AND COMPOSITION THEREOF, AND USE 江苏恩华药业股份有限公司 2026-05-21 — — WO disclosed
US-20250188075-A1 SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS THE BROAD INSTITUTE, INC. 2025-06-12 — — US disclosed
EP-4469457-A1 SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS The Broad Institute Inc. (US) 2024-12-04 — — EP disclosed
WO-2023147015-A1 SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS THE BROAD INSTITUTE, INC. (US) 2023-08-03 — — WO disclosed
EP-3405477-B1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2023-06-07 — — EP disclosed
EP-3458459-B1 MACROCYCLIC INDOLE DERIVATIVES BAYER AG (DE) 2022-04-27 — — EP disclosed
CN-109715632-B Macrocyclic indole derivatives 拜尔公开股份有限公司 2021-10-26 — — CN disclosed
US-11072634-B2 Inhibitors of transglutaminases ZEDIRA GMBH (DE) 2021-07-27 — — US disclosed
US-10981932-B2 Macrocyclic indole derivatives BAYER AKTIENGESELLSCHAFT (DE) 2021-04-20 — — US disclosed
US-20200087322-A1 MACROCYCLIC INDOLE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-03-19 — — US disclosed
US-7507729-B2 for the treatment of cognitive disorders, anxiety, schizophrenia, and Alzheimer's disease; ligands; GABA A alpha 5 receptor inhibitors; 3-bromo-10-chloro-6-(2-oxo-pyrrolidin-1-ylmethyl)-9H-imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine HOFFMANN-LA ROCHE INC. (US) 2009-03-24 — — US disclosed
CN-101287738-A Imidazo benzodiazepine derivatives HOFFMANN LA ROCHE (CH) 2008-10-15 — — CN disclosed
EP-1937688-A1 IMIDAZO BENZODIAZEPINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-07-02 — — EP disclosed
CN-100383278-C Partial plating method, partially-plated resin base, method for manufacturing multilayer circuit board ZEON CORP (JP) 2008-04-23 — — CN disclosed
WO-2007042421-A1 IMIDAZO BENZODIAZEPINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-04-19 — — WO disclosed
US-20070082890-A1 Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT 2007-04-12 — — US disclosed
US-20050153059-A1 Partial plating method, partially-plated resin base, method for manufacturing multilayered circuit board ZEON CORPORATION (JP) 2005-07-14 — — US disclosed
CN-1639384-A Partial plating method, partially-plated resin base, method for manufacturing multilayer circuit board ZEON CORP (JP) 2005-07-13 — — CN disclosed
US-20040237295-A1 Multilayer circuit board and resin base material, and its production method ZEON CORPORATION (JP) 2004-12-02 — — US disclosed
CN-1552174-A Mulitilayer circuit board, resin base material, and its production method �ձ�������ʽ���� 2004-12-01 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10981932-B2 Macrocyclic indole derivatives CCND2, IDO1, CCNT2 LMNA 1055/4885KDM4E 1858/4885FFAR1 2224/4885
US-20070082890-A1 Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives GABRA5, GABRA1, GABRA4 LMNA 3824/4885KDM4E 1207/4885FFAR1 363/4885
US-20200087322-A1 MACROCYCLIC INDOLE DERIVATIVES CCND2, CCNA1, CCNT2 LMNA 933/4885KDM4E 2044/4885FFAR1 2083/4885
US-11072634-B2 Inhibitors of transglutaminases TGM2, TGM3, TGM1 LMNA 2426/4885KDM4E 911/4885FFAR1 4075/4885
US-20250188075-A1 SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS CSNK1A1, CSNK2A1, CSNK1A1L LMNA 3601/4885KDM4E 853/4885FFAR1 4344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.